Value of B-type natriuretic peptide for identifying significantly elevated pulmonary artery wedge pressure in patients treated for established chronic heart failure

It has been suggested that plasma B-type natriuretic peptide (BNP) level may be used as a noninvasive biomarker of the adequacy of long-term heart failure therapy. The effect of contemporary therapy on the relation between BNP measured using modern commercially available assays and cardiac filling p...

Full description

Saved in:
Bibliographic Details
Published in:The American journal of cardiology 2005-04, Vol.95 (7), p.883
Main Authors: Parsonage, William A, Galbraith, Andrew J, Koerbin, Gary L, Potter, Julia M
Format: Article
Language:English
Subjects:
Blood pressure
Coronary vessels
Disease management
Heart failure
Peptides
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites
container_end_page
container_issue 7
container_start_page 883
container_title The American journal of cardiology
container_volume 95
creator Parsonage, William A
Galbraith, Andrew J
Koerbin, Gary L
Potter, Julia M
description It has been suggested that plasma B-type natriuretic peptide (BNP) level may be used as a noninvasive biomarker of the adequacy of long-term heart failure therapy. The effect of contemporary therapy on the relation between BNP measured using modern commercially available assays and cardiac filling pressures has not been studied in detail, because most of the original studies predate these developments. The investigators sought to assess the diagnostic accuracy of BNP to identify significantly elevated pulmonary capillary wedge pressure (PCWP) in a group of patients with severe chronic heart failure on treatment. BNP correlated well with PCWP (r = 0.50, p 15 mm Hg was only 74%, largely because of poor sensitivity or a large number of false-negative test results. Maximizing medical therapy irrespective of plasma BNP results remains the best approach to managing chronic heart failure. [PUBLICATION ABSTRACT]
format article
fullrecord <record><control><sourceid>proquest</sourceid><recordid>TN_cdi_proquest_journals_230359987</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>820242781</sourcerecordid><originalsourceid>FETCH-proquest_journals_2303599873</originalsourceid><addsrcrecordid>eNqNjUFOwzAQRS1EJQLlDiP2keKG0noLAnEAxLZyk3EylbGNPQblPhyUAXEAVl9f89-bM9Xo_c602uj-XDVd121ao2_Nhbos5SRV6-1do75era8I0cF9y0tCCJYz1YxMAyRMTCOCixkkA5NbKExQaArkaLCB_QLo8cMyjpCqf4vB5gVsZpT4xHFCSBlLESNQgGSZxFOAM_4yP2osbI-eyix9mHMM8npGcYCz5IVcq5WzvuD1X16pm6fHl4fnNuX4XgU_nGLNQU6HTd_1W2P2u_5fo29aUGDz</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>230359987</pqid></control><display><type>article</type><title>Value of B-type natriuretic peptide for identifying significantly elevated pulmonary artery wedge pressure in patients treated for established chronic heart failure</title><source>ScienceDirect Journals</source><creator>Parsonage, William A ; Galbraith, Andrew J ; Koerbin, Gary L ; Potter, Julia M</creator><creatorcontrib>Parsonage, William A ; Galbraith, Andrew J ; Koerbin, Gary L ; Potter, Julia M</creatorcontrib><description>It has been suggested that plasma B-type natriuretic peptide (BNP) level may be used as a noninvasive biomarker of the adequacy of long-term heart failure therapy. The effect of contemporary therapy on the relation between BNP measured using modern commercially available assays and cardiac filling pressures has not been studied in detail, because most of the original studies predate these developments. The investigators sought to assess the diagnostic accuracy of BNP to identify significantly elevated pulmonary capillary wedge pressure (PCWP) in a group of patients with severe chronic heart failure on treatment. BNP correlated well with PCWP (r = 0.50, p &lt;0.001), but the diagnostic accuracy of the test to identify patients with PCWP &gt;15 mm Hg was only 74%, largely because of poor sensitivity or a large number of false-negative test results. Maximizing medical therapy irrespective of plasma BNP results remains the best approach to managing chronic heart failure. [PUBLICATION ABSTRACT]</description><identifier>ISSN: 0002-9149</identifier><identifier>EISSN: 1879-1913</identifier><identifier>CODEN: AJCDAG</identifier><language>eng</language><publisher>New York: Elsevier Limited</publisher><subject>Blood pressure ; Coronary vessels ; Disease management ; Heart failure ; Peptides</subject><ispartof>The American journal of cardiology, 2005-04, Vol.95 (7), p.883</ispartof><rights>Copyright Elsevier Sequoia S.A. Apr 1, 2005</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784</link.rule.ids></links><search><creatorcontrib>Parsonage, William A</creatorcontrib><creatorcontrib>Galbraith, Andrew J</creatorcontrib><creatorcontrib>Koerbin, Gary L</creatorcontrib><creatorcontrib>Potter, Julia M</creatorcontrib><title>Value of B-type natriuretic peptide for identifying significantly elevated pulmonary artery wedge pressure in patients treated for established chronic heart failure</title><title>The American journal of cardiology</title><description>It has been suggested that plasma B-type natriuretic peptide (BNP) level may be used as a noninvasive biomarker of the adequacy of long-term heart failure therapy. The effect of contemporary therapy on the relation between BNP measured using modern commercially available assays and cardiac filling pressures has not been studied in detail, because most of the original studies predate these developments. The investigators sought to assess the diagnostic accuracy of BNP to identify significantly elevated pulmonary capillary wedge pressure (PCWP) in a group of patients with severe chronic heart failure on treatment. BNP correlated well with PCWP (r = 0.50, p &lt;0.001), but the diagnostic accuracy of the test to identify patients with PCWP &gt;15 mm Hg was only 74%, largely because of poor sensitivity or a large number of false-negative test results. Maximizing medical therapy irrespective of plasma BNP results remains the best approach to managing chronic heart failure. [PUBLICATION ABSTRACT]</description><subject>Blood pressure</subject><subject>Coronary vessels</subject><subject>Disease management</subject><subject>Heart failure</subject><subject>Peptides</subject><issn>0002-9149</issn><issn>1879-1913</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2005</creationdate><recordtype>article</recordtype><recordid>eNqNjUFOwzAQRS1EJQLlDiP2keKG0noLAnEAxLZyk3EylbGNPQblPhyUAXEAVl9f89-bM9Xo_c602uj-XDVd121ao2_Nhbos5SRV6-1do75era8I0cF9y0tCCJYz1YxMAyRMTCOCixkkA5NbKExQaArkaLCB_QLo8cMyjpCqf4vB5gVsZpT4xHFCSBlLESNQgGSZxFOAM_4yP2osbI-eyix9mHMM8npGcYCz5IVcq5WzvuD1X16pm6fHl4fnNuX4XgU_nGLNQU6HTd_1W2P2u_5fo29aUGDz</recordid><startdate>20050401</startdate><enddate>20050401</enddate><creator>Parsonage, William A</creator><creator>Galbraith, Andrew J</creator><creator>Koerbin, Gary L</creator><creator>Potter, Julia M</creator><general>Elsevier Limited</general><scope>7TS</scope><scope>8FD</scope><scope>FR3</scope><scope>K9.</scope><scope>M7Z</scope><scope>NAPCQ</scope><scope>P64</scope></search><sort><creationdate>20050401</creationdate><title>Value of B-type natriuretic peptide for identifying significantly elevated pulmonary artery wedge pressure in patients treated for established chronic heart failure</title><author>Parsonage, William A ; Galbraith, Andrew J ; Koerbin, Gary L ; Potter, Julia M</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-proquest_journals_2303599873</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2005</creationdate><topic>Blood pressure</topic><topic>Coronary vessels</topic><topic>Disease management</topic><topic>Heart failure</topic><topic>Peptides</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Parsonage, William A</creatorcontrib><creatorcontrib>Galbraith, Andrew J</creatorcontrib><creatorcontrib>Koerbin, Gary L</creatorcontrib><creatorcontrib>Potter, Julia M</creatorcontrib><collection>Physical Education Index</collection><collection>Technology Research Database</collection><collection>Engineering Research Database</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Biochemistry Abstracts 1</collection><collection>Nursing &amp; Allied Health Premium</collection><collection>Biotechnology and BioEngineering Abstracts</collection><jtitle>The American journal of cardiology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Parsonage, William A</au><au>Galbraith, Andrew J</au><au>Koerbin, Gary L</au><au>Potter, Julia M</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Value of B-type natriuretic peptide for identifying significantly elevated pulmonary artery wedge pressure in patients treated for established chronic heart failure</atitle><jtitle>The American journal of cardiology</jtitle><date>2005-04-01</date><risdate>2005</risdate><volume>95</volume><issue>7</issue><spage>883</spage><pages>883-</pages><issn>0002-9149</issn><eissn>1879-1913</eissn><coden>AJCDAG</coden><abstract>It has been suggested that plasma B-type natriuretic peptide (BNP) level may be used as a noninvasive biomarker of the adequacy of long-term heart failure therapy. The effect of contemporary therapy on the relation between BNP measured using modern commercially available assays and cardiac filling pressures has not been studied in detail, because most of the original studies predate these developments. The investigators sought to assess the diagnostic accuracy of BNP to identify significantly elevated pulmonary capillary wedge pressure (PCWP) in a group of patients with severe chronic heart failure on treatment. BNP correlated well with PCWP (r = 0.50, p &lt;0.001), but the diagnostic accuracy of the test to identify patients with PCWP &gt;15 mm Hg was only 74%, largely because of poor sensitivity or a large number of false-negative test results. Maximizing medical therapy irrespective of plasma BNP results remains the best approach to managing chronic heart failure. [PUBLICATION ABSTRACT]</abstract><cop>New York</cop><pub>Elsevier Limited</pub></addata></record>
fulltext fulltext
identifier ISSN: 0002-9149
ispartof The American journal of cardiology, 2005-04, Vol.95 (7), p.883
issn 0002-9149
1879-1913
language eng
recordid cdi_proquest_journals_230359987
source ScienceDirect Journals
subjects Blood pressure
Coronary vessels
Disease management
Heart failure
Peptides
title Value of B-type natriuretic peptide for identifying significantly elevated pulmonary artery wedge pressure in patients treated for established chronic heart failure
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-05T01%3A10%3A47IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Value%20of%20B-type%20natriuretic%20peptide%20for%20identifying%20significantly%20elevated%20pulmonary%20artery%20wedge%20pressure%20in%20patients%20treated%20for%20established%20chronic%20heart%20failure&rft.jtitle=The%20American%20journal%20of%20cardiology&rft.au=Parsonage,%20William%20A&rft.date=2005-04-01&rft.volume=95&rft.issue=7&rft.spage=883&rft.pages=883-&rft.issn=0002-9149&rft.eissn=1879-1913&rft.coden=AJCDAG&rft_id=info:doi/&rft_dat=%3Cproquest%3E820242781%3C/proquest%3E%3Cgrp_id%3Ecdi_FETCH-proquest_journals_2303599873%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=230359987&rft_id=info:pmid/&rfr_iscdi=true